Neurological Surgery 脳神経外科47巻11号

2019年11月発行

症例

c-Myc転座とBcl-2蛋白発現を有するhigh grade B-cell lymphomaの急速進行例

著者： 森永裕介¹ 新居浩平¹ 坂本王哉¹ 井上律郎¹ 光武尚史¹ 花田迅貫¹ 堤正則¹

所属機関： ¹福岡大学筑紫病院脳神経外科

ページ範囲：P.1179 - P.1184

Ⅰ．はじめに
　今回われわれは痙攣発症から第45病日で死亡に至ったc-Myc転座とB-cell lymphoma（Bcl)-2蛋白発現を有するprimary central nervous system lymphoma（high grade B-cell lymphoma［HGBL］of PCNSL）の急速進行例を経験したため，文献的考察を加えて報告する．

参考文献

1) Abramson JS：The spectrum of double hit lymphomas. Hematol Oncol Clin North Am 30：1239-1249, 2016

2) Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM：Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403（6769）：503-511, 2000

3) Beham-Schmid C：Aggressive lymphoma 2016：revision of the WHO classification. Memo 10：248-254, 2017

4) Cai Q, Medeiros LJ, Xu X, Young KH：MYC-driven aggressive B-cell lymphomas：biology, entity, differential diagnosis and clinical management. Oncotarget 6：38591-38616, 2015

5) Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC：Induction of apoptosis in fibroblasts by c-myc protein. Cell 69：119-128, 1992

6) Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB：Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30：3460-3467, 2012

7) Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT：Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 21：296-305, 2019

8) Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC：Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103：275-282, 2004.

9) Horn H, Ziepert M, Becher C, Barth TFE, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G；German High-Grade Non-Hodgkin Lymphoma Study Group：MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121：2253-2263, 2013

10) Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD：Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30：3452-3459, 2012

11) 菊地　淳，百瀬修二，田丸淳一，得平道英：MYCのタンパク発現量を基軸とした高悪性度B細胞性リンパ腫の臨床病態の解明．埼玉医大誌43：165-167, 2017

12) Lee JT, Innes DJ Jr, Williams ME：Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 84：1454-1459, 1989

13) Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DCS, Roberts AW：In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A 105：17961-17966, 2008

. Nature 348（6299）：331-333, 1990

15) Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW（eds）:WHO Classification of Tumours of Haematopietic and Lymphoid Tissues. IARC, Lyon, France, 2008, pp.233-244

to immortalize pre-B cells. Nature 335（6189）：440-442, 1988